IONS Quote, Financials, Valuation and Earnings

Catalyst Pharmaceuticals has a net margin of -111.65% compared to Ionis Pharmaceuticals's net margin of 40.12%. Ionis Pharmaceuticals's return on equity of -100.15% beat Catalyst Pharmaceuticals's return on equity of 29.43%.

Ionis Pharmaceuticals has a consensus price target of $57.54, signalling upside risk potential of 78.37%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $34.00 which suggests that it could grow by 45.49%. Given that Ionis Pharmaceuticals has higher upside potential than Catalyst Pharmaceuticals, analysts believe Ionis Pharmaceuticals is more attractive than Catalyst Pharmaceuticals.

Ionis Pharmaceuticals has a beta of 0.151, which suggesting that the stock is 84.865% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.697, suggesting its less volatile than the S&P 500 by 30.252%.

Ionis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

Ionis Pharmaceuticals quarterly revenues are $131.6M, which are smaller than Catalyst Pharmaceuticals quarterly revenues of $141.4M. Ionis Pharmaceuticals's net income of -$146.9M is lower than Catalyst Pharmaceuticals's net income of $56.7M. Notably, Ionis Pharmaceuticals's price-to-earnings ratio is -- while Catalyst Pharmaceuticals's PE ratio is 14.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals is 6.87x versus 5.50x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Dynavax Technologies has a net margin of -111.65% compared to Ionis Pharmaceuticals's net margin of -140.98%. Ionis Pharmaceuticals's return on equity of -100.15% beat Dynavax Technologies's return on equity of -9.78%.

Ionis Pharmaceuticals has a consensus price target of $57.54, signalling upside risk potential of 78.37%. On the other hand Dynavax Technologies has an analysts' consensus of $23.28 which suggests that it could grow by 147.34%. Given that Dynavax Technologies has higher upside potential than Ionis Pharmaceuticals, analysts believe Dynavax Technologies is more attractive than Ionis Pharmaceuticals.

Ionis Pharmaceuticals has a beta of 0.151, which suggesting that the stock is 84.865% less volatile than S&P 500. In comparison Dynavax Technologies has a beta of 1.261, suggesting its more volatile than the S&P 500 by 26.142%.

Ionis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dynavax Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals pays -- of its earnings as a dividend. Dynavax Technologies pays out -- of its earnings as a dividend.

Ionis Pharmaceuticals quarterly revenues are $131.6M, which are larger than Dynavax Technologies quarterly revenues of $68.2M. Ionis Pharmaceuticals's net income of -$146.9M is lower than Dynavax Technologies's net income of -$96.1M. Notably, Ionis Pharmaceuticals's price-to-earnings ratio is -- while Dynavax Technologies's PE ratio is 54.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals is 6.87x versus 4.52x for Dynavax Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -111.65% compared to Ionis Pharmaceuticals's net margin of 50.24%. Ionis Pharmaceuticals's return on equity of -100.15% beat Johnson & Johnson's return on equity of 30.18%.

Ionis Pharmaceuticals has a consensus price target of $57.54, signalling upside risk potential of 78.37%. On the other hand Johnson & Johnson has an analysts' consensus of $170.19 which suggests that it could grow by 10.36%. Given that Ionis Pharmaceuticals has higher upside potential than Johnson & Johnson, analysts believe Ionis Pharmaceuticals is more attractive than Johnson & Johnson.

Ionis Pharmaceuticals has a beta of 0.151, which suggesting that the stock is 84.865% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.425, suggesting its less volatile than the S&P 500 by 57.471%.

Ionis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.22% to investors and pays a quarterly dividend of $1.24 per share. Ionis Pharmaceuticals pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ionis Pharmaceuticals quarterly revenues are $131.6M, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Ionis Pharmaceuticals's net income of -$146.9M is lower than Johnson & Johnson's net income of $11B. Notably, Ionis Pharmaceuticals's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 17.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals is 6.87x versus 4.19x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

OptiNose has a net margin of -111.65% compared to Ionis Pharmaceuticals's net margin of -1.61%. Ionis Pharmaceuticals's return on equity of -100.15% beat OptiNose's return on equity of --.

Ionis Pharmaceuticals has a consensus price target of $57.54, signalling upside risk potential of 78.37%. On the other hand OptiNose has an analysts' consensus of $18.00 which suggests that it could grow by 91.69%. Given that OptiNose has higher upside potential than Ionis Pharmaceuticals, analysts believe OptiNose is more attractive than Ionis Pharmaceuticals.

Ionis Pharmaceuticals has a beta of 0.151, which suggesting that the stock is 84.865% less volatile than S&P 500. In comparison OptiNose has a beta of -0.879, suggesting its less volatile than the S&P 500 by 187.86%.

Ionis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OptiNose offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals pays -- of its earnings as a dividend. OptiNose pays out -- of its earnings as a dividend.

Ionis Pharmaceuticals quarterly revenues are $131.6M, which are larger than OptiNose quarterly revenues of $22.4M. Ionis Pharmaceuticals's net income of -$146.9M is lower than OptiNose's net income of -$360K. Notably, Ionis Pharmaceuticals's price-to-earnings ratio is -- while OptiNose's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals is 6.87x versus 1.23x for OptiNose. Usually stocks with elevated PS ratios are considered overvalued.